India’s Regulatory System Is Turning More Digital, Faster, More Innovation-Friendly

Several changes are underway that affect us in clinical practice:

• The DCGI / CDSCO is pushing faster drug approvals, especially for rare disease therapies and advanced treatments (like gene therapies).

• Drug licensing systems are being digitized: state + central regulatory authority applications, review dashboards, national unified portals etc.

• India is aligning regulatory practices toward global benchmarks (USFDA, EMA etc.), which means safety, manufacturing quality, clinical trial standards are being tightened.

For us doctors, this means we may get access to newer drugs sooner, but also greater responsibility: ensuring our clinical trial data, adverse event reporting, and prescribing behaviour are aligned with higher standards. It also means we must stay updated, so we’re not prescribing “off label” or outdated options when better ones become available.